2.75
+1.48%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sunshine Biopharma
From its filings with the US Securities and Exchange Commission
Sunshine Biopharma is based in Fort Lauderdale, Florida and is incorporated in Colorado. Its shares trade on Nasdaq under the ticker SBFM. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $36.3m and a net loss of $6.0m. At that date it held total assets of $30.1m and shareholders' equity of $23.0m.
In-licensing and Supply Agreements: Nora Pharma acquires the rights to import, market, sell and distribute the products in Canada by purchasing the drug dossiers from strategic partners. Nora Pharma then files the dossiers with Health Canada to obtain regulatory approval prior to marketing. The approval process at Health Canada takes on average of 12 months. The products are sold under Nora Pharma label.
Cross-licensing: Nora Pharma acquires the rights to import, market, sell and distribute the products in Canada by receiving an authorization letter from pharmaceutical partners. The partners’ products are already approved in Canada but we are still required to obtain our own approval from Health Canada, which takes on average 45-60 days. The products are sold under Nora Pharma label.
Distribution Agreements: Nora Pharma acquires the rights to market, sell and distribute the products in Canada by signing a distribution agreement with pharmaceutical partners. The partners’ products are already approved by Health Canada. The products are sold under the partners’ label.
On April 20, 2022, we filed a provisional patent application in the United States covering our K1.1 mRNA molecules.
Quoted from its 10-K, filed 3 Apr 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 15 Aug 2008
- Employees
- 46
- Website
- sunshinebiopharma.com ↗
- Head office
- 333 LAS OLAS WAY, FORT LAUDERDALE, FL, 33301
- Incorporated in
- CO
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Steve SlilatyChairman of the Board, President, Chief Executive Officer, since 2009$1.3m
- Mr. Camille SebaalyChief Financial Officer, Secretary, since 2009$352,031
- Dr. Abderrazzak MerzoukiChief Operating Officer, Director, since 2016$366,625
- Mr. Michel RoyChief Commercial Officer
- Dr. Andrew KellerIndependent Director$80,000
- Dr. Rabi KiderchahIndependent Director$80,000
- Mr. David NatanIndependent Director$80,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sunshine Biopharma employs 46 full-time staff members to support its operations.
- The company owns NoraPharma Inc. with 50 generic prescription drugs in Canada.
- Adva-27a targets pancreatic cancer as a small chemotherapy molecule for patients.
Weaknesses
- The firm has only 46 employees, which limits its operational capacity.
- Sunshine Biopharma relies on proprietary drugs like K1.1 mRNA for liver cancer.
- SBFM-PL4 is an anti-coronavirus compound that requires further development and testing.
Opportunities
- The company can expand its portfolio of 27 additional generic prescription drugs.
- Sunshine Biopharma Canada Inc. sells non-prescription over-the-counter products to consumers.
- Researching life-saving medicines in oncology offers growth potential for the firm.
Threats
- Competition in the biotechnology sector may impact the success of Adva-27a.
- Regulatory changes could affect the commercialization of K1.1 mRNA for liver cancer.
- Market demand for SBFM-PL4 might fluctuate due to changing coronavirus trends.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.